Diabetic cardiomyopathy: definition, diagnosis criteria, treatment directions and prevention of heart failure
https://doi.org/10.21886/2712-8156-2020-1-2-93-101
Abstract
The topical review discusses various points of view related to terminology, diagnostic criteria, difficulties in assessing the prevalence and stages of diabetic cardiomyopathy, presents used in clinical practice and potential instrumental and laboratory diagnostic methods, provides therapeutic methods and strategic directions for the treatment of this condition and the prevention of chronic heart failure.
About the Authors
N. A. Koziolova
Academician Ye.A. Wagner Perm State Medical University
Russian Federation
Russian Federation
Natalya A. Koziolova, Dr. Ci. (Med.), Prof.
Perm
P. G. Karavaev
Academician Ye.A. Wagner Perm State Medical University
Russian Federation
Russian Federation
Pavel G. Karavaev
Perm
A. S. Veklich
Academician Ye.A. Wagner Perm State Medical University
Russian Federation
Russian Federation
Andrey S. Veklich
Perm
References
1. Trachanas K., Sideris S., Aggeli C., Poulidakis E., Gatzoulis K., Tousoulis D., et al. Diabetic cardiomyopathy: from pathophysiology to treatment. Hellenic J Cardiol.2014;55:411– 421. PMID: 25243440
2. Lundbaek K. Diabetic angiopathy. A specific vascular disease. Lancet. 1954;263:377–379. https://doi.org/10.1016/S0140-6736(54)90924-1
3. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A., et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595- 602. https://doi.org/10.1016/0002-9149(72)90595-4
4. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure; the Framingham study. Am J Cardiol. 1974;34:29–34. https://doi.org/10.1016/0002-9149(74)90089-7
5. Penpargkul S., Fein F., Sonnenblick E.H., Scheuer J. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981;13:303-9. https://doi.org/10.1016/0022-2828(81)90318-7
6. Trost S.U., Belke D.D., Bluhm W.F., Meyer M., Swanson E., Dillmann W.H. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51:1166–71. https://doi.org/10.2337/diabetes.51.4.1166
7. Lorenzo-Almorós A., Tuñón J., Orejas M., Cortés M., Egido J., Lorenzo Ó. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16(1):28. https://doi.org/10.1186/s12933-017-0506-x
8. Marcinkiewicz A., Ostrowski S., Drzewoski J. Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Diabetol Metab Syndr. 2017;9:21. https://doi.org/10.1186/s13098-017-0219-z
9. Lee W.S., Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med. 2017;32(3):404- 421. https://doi.org/10.3904/kjim.2016.208.
10. Dillmann W.H. Diabetic Cardiomyopathy. Circ Res. 2019;124(8):1160-1162. https://doi.org/10.1161/CIRCRESAHA.118.314665
11. Jia G., Hill M.A., Sowers J.R. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122(4):624-638. https://doi.org/10.1161/CIRCRESAHA.117.311586
12. Jia G., DeMarco V.G., Sowers J.R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144-153. https://doi.org/10.1038/nrendo.2015.216
13. Mellor K.M., Bell J.R., Ritchie R.H., Delbridge L.M. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin Exp Pharmacol Physiol. 2013;40(1):56-61. https://doi.org/10.1111/j.1440-1681.2012.05738.x
14. Guo R., Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070-2077. https://doi.org/10.1016/j.bbadis.2017.03.013
15. Borghetti G., von Lewinski D., Eaton D..M, Sourij H., Houser S.R., Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514. https://doi.org/10.3389/fphys.2018.01514
16. Konduracka E., Cieslik G., Galicka-Latala D., Rostoff P., Pietrucha A., Latacz P., et al. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol. 2013;50(4):597-606. https://doi.org/10.1007/s00592-013-0455-0
17. Dandamudi S., Slusser J., Mahoney D.W., Redfield M.M., Rodeheffer R.J., Chen H.H. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail. 2014;20(5):304-9. https://doi.org/10.1016/j.cardfail.2014.02.007
18. Караваев П. Г., Веклич А. С., Козиолова Н. А. Диабетическая кардиомиопатия: особенности сердечно-сосудистого ремоделирования. Российский кардиологический журнал. 2019;24(11):42–47. https://doi.org/10.15829/1560-4071-2019-11-42-47
19. Kenny H.C., Abel E.D. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124(1):121-141. https://doi.org/10.1161/CIRCRESAHA.118.311371
20. Echouffo-Tcheugui J.B., Xu H., DeVore A.D., Schulte P.J., Butler J., Yancy C.W., et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The GuidelinesHeart Failure registry. Am Heart J. 2016;182:9-20. https://doi.org/10.1016/j.ahj.2016.07.025
21. Loncarevic B., Trifunovic D., Soldatovic I., Vujisic-Tesic B. Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. BMC Cardiovasc Disord. 2016;16(1):242. https://doi.org/10.1186/s12872-016-0395-z
22. Seferović P.M., Paulus W.J. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718-1727c. https://doi.org/10.1093/eurheartj/ehv134/
23. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543-567. https://doi.org/10.1210/er.2003-0012
24. Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther. 2018;8(1):47-56. https://doi.org/10.21037/cdt.2018.01.03
25. Alonso N., Moliner P., Mauricio D. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. Adv Exp Med Biol. 2018;1067:197-217. https://doi.org/10.1007/5584_2017_105
26. Gil K.E., Pawlak A., Gil R.J., Frontczak-Baniewicz M., Bil J. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Adv Med Sci. 2016;61(2):331-343. https://doi.org/10.1016/j.advms.2016.07.001
27. Guo R., Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070-2077. https://doi.org/10.1016/j.bbadis.2017.03.013
28. Ghosh N., Katare R. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides. Cardiovasc Diabetol. 2018;17(1):43. https://doi.org/10.1186/s12933-018-0684-1
29. Hafstad A.D., Boardman N., Aasum E. How exercise may amend metabolic disturbances in diabetic cardiomyopathy. Antioxid Redox Signal. 2015;22(17):1587- 1605. https://doi.org/10.1089/ars.2015.6304
30. Waldman M., Cohen K., Yadin D., Nudelman V., Gorfil D., Laniado-Schwartzman M., et al. Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'. Cardiovasc Diabetol. 2018;17(1):111. https://doi.org/10.1186/s12933-018-0754-4
31. Chen Q., Thompson J., Hu Y., Das A., Lesnefsky EJ. Metformin attenuates ER stress-induced mitochondrial dysfunction. Transl Res. 2017;190:40-50. https://doi.org/10.1016/j.trsl.2017.09.003
32. Borghetti G., von Lewinski D., Eaton D.M., Sourij H., Houser S.R., Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514. https://doi.org/10.3389/fphys.2018.01514
33. Wu L., Wang K., Wang W., Wen Z., Wang P., Liu L., Wang D.W. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway. Aging Cell. 2018;17(4):e12763. https://doi.org/10.1111/acel.12763
34. Levelt E., Gulsin G., Neubauer S., McCann G.P. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol. 2018;178(4):R127-R139. https://doi.org/10.1530/EJE-17-0724
35. Pan G., Deshpande M., Pang H., Palaniyandi S.S. Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians. Eur J Pharmacol. 2018;839:76-81. https://doi.org/10.1016/j.ejphar.2018.09.021
36. Liu W., Gong W., He M., Liu Y., Yang Y., Wang M., et al. Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats. J Diabetes Res. 2018;2018:9232065. https://doi.org/10.1155/2018/9232065
37. Sivasankar D., George M., Sriram D.K. Novel approaches in the treatment of diabetic cardiomyopathy. Biomed Pharmacother. 2018;106:1039-1045. https://doi.org/10.1016/j.biopha.2018.07.051
38. Yilmaz S., Canpolat U., Aydogdu S., Abboud H.E. Diabetic Cardiomyopathy; Summary of 41 Years. Korean Circ J. 2015;45(4):266-272. https://doi.org/10.4070/kcj.2015.45.4.266
39. Di Luigi L., Corinaldesi C., Colletti M., Scolletta S., Antinozzi C., Vannelli G.B., et al. Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. Inflammation. 2016;39(3):1238- 52. https://doi.org/10.1007/s10753-016-0359-6
40. Carillion A., Feldman S., Na N., Biais M., Carpentier W., Birenbaum A., et al. Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS One. 2017;12(7):e0180103. https://doi.org/10.1371/journal.pone.0180103
41. Yang H., Feng A., Lin S., Yu L., Lin X., Yan X., et al. Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis. 2018;9(2):227. https://doi.org/10.1038/s41419-018-0307-5
42. Zhang L., Ding W.Y., Wang Z.H., Tang M.X., Wang F., Li Y., et al. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med. 2016;14(1):109. https://doi.org/10.1186/s12967-016-0849-1
43. Gollmer J., Zirlik A., Bugger H. Mitochondrial Mechanisms in Diabetic Cardiomyopathy. Diabetes Metab J. 2020;44(1):33- 53. https://doi.org/10.4093/dmj.2019.0185
44. Tian J., Zhao Y., Liu Y., Liu Y., Chen K., Lyu S. Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective. Oxid Med Cell Longev. 2017;2017:8214541. https://doi.org/10.1155/2017/8214541
45. Fang W.J., Wang C.J., He Y., Zhou Y.L., Peng X.D., Liu S.K. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation. Acta Pharmacol Sin. 2018;39(1):59-73. https://doi.org/10.1038/aps.2017.50
46. Wen H.L., Liang Z.S., Zhang R., Yang K. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol. 2013;12:50. https://doi.org/10.1186/1475-2840-12-50
47. Huynh K., Bernardo B.C., McMullen J.R., Ritchie R.H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142(3):375-415. https://doi.org/10.1016/j.pharmthera.2014.01.003.
48. Park I.H., Song Y.S., Joo H.W., Shen G.Y., Seong J.H., Shin N.K., et al. Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy. Diabetes Metab J. 2020;44(1):173-185. https://doi.org/10.4093/dmj.2018.0211
Review
For citations:
Koziolova N.A., Karavaev P.G., Veklich A.S. Diabetic cardiomyopathy: definition, diagnosis criteria, treatment directions and prevention of heart failure. South Russian Journal of Therapeutic Practice. 2020;1(2):93-101. (In Russ.) https://doi.org/10.21886/2712-8156-2020-1-2-93-101
Views:
1327
Email this article 